Management of the older person with atrial fibrillation

Journal of the American Geriatrics Society

Volumn 47, Issue 6, 1999, Pages 740-748

  Aronow, Wilbert S ^a,b  

^a HEBREW HOSPITAL HOME   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Atrial fibrillation; Stroke; Thromboembolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; VERAPAMIL; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; CARDIOVERSION; DRUG INDICATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PACEMAKER; PRECIPITATION; PUBLICATION; REVIEW; SINUS RHYTHM; STROKE; SYNCOPE; TREATMENT CONTRAINDICATION; VERTIGO;

EID: 0033030611     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1999.tb01602.x     Document Type: Review

References (86)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
2. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc 1996;44:521-523.
3. Furberg CD, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74: 236-241.
4. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc 1998;46:1423-1424.
5. Psaty BM, Manolio TA, Kuller LH et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455-2461.
6. Danias PG, Caulfield TA, Weigner MJ et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998;31: 588-592.
7. Aronow WS, Ahn C, Kronzon I. Echocardiographic findings associated with atrial fibrillation in 1,699 patients aged >60 years. Am J Cardiol 1995;76: 1191-1192.
8. Sawin CT, Geller A, Wolf PA et al. Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331: 1249-1252.
9. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982;306:1018-1022.
10. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 1998;98:946-952.
11. Aronow WS, Ahn C, Mercando AD, Epstein S. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1,359 patients, mean age 81 years, with heart disease. Am J Cardiol 1995;75:182-184.
12. Pollak A, Falk RH. Pacemaker therapy in patients with atrial fibrillation. Am Heart J 1993;125:824-830.
13. Aronow WS, Landa D, Plasencia G et al. Verapamil in atrial fibrillation and atrial flutter. Clin Pharmacol Ther 1979;26:578-583.
14. Salerno DM, Dias VC, Kleiger RE et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. Am J Cardiol 1989;63:1046-1051.
15. Aronow WS, Uyeyama RR. Treatment of arrhythmias with pindolol. Clin Pharmacol Ther 1972;13:15-22.
16. Aronow WS, Van Camp S, Turbow M et al. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther 1979;25:149-153.
17. Aronow WS. Use of beta-adrenergic blockers in antiarrhythmic therapy. Practical Cardiol 1986;12(6):75-89.
18. Abrams J, Allen J, Allin D et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: A multicenter double-blind clinical trial. Am Heart J 1985;110:913-922.
19. Falk RH, Knowlton AA, Bernard SA et al. Digoxin for converting recent onset atrial fibrillation to sinus rhythm: A randomized, double-blinded trial. Ann Intern Med 1987;106:503-506.
20. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: A drug whose time has gone? Ann Intern Med 1991;114:573-575.
21. Aronow WS. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients: Which is the preferred treatment? Drugs Aging 1991;1:98-103.
22. Lang R, Klein HD, Weiss E et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983;83:491-499.
23. Roth A, Harrison E, Milani G et al. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986;73:316-324.
24. David D, Segni ED, Klein HO et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979;44:1378-1382.
25. Gold RL, Haffajee CI, Charos G et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
26. Chun SH, Sager PT, Stevenson WG et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
27. Williamson BD, Man KC, Daoud E et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994;331:910-917.
28. Feld GK, Fleck P, Fujimura O et al. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994;90:2299-2307.
29. Fitzpatrick AP, Kourouyan HD, Siu A et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996;131:499-507.
30. Cox JL, Boineau JP, Schuessler RB et al. Successful surgical treatment of atrial fibrillation: Review and clinical update. JAMA 1991;266:1976-1980.
31. Leitch JW, Klein G, Yee R, Guiraudon G. Sinus node-atrioventricular node isolation: Long-term results with the "Corridor" operation for atrial fibrillation. J Am Coll Cardiol 1991;17:970-975.
32. Shinbane JS, Wood MA, Jensen DN et al. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709-715.
33. Schumacher B, Luderitz B. Rate issues in atrial fibrillation: Consequences of tachycardia and therapy for rate control. Am J Cardiol 1998;82:29-36N.
34. Sgarbossa EB, Pinski SL, Maloney JD et al. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities. Circulation 1993;88:1045-1053.
35. Andersen HR, Thuesen L, Bagger JP et al. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet 1994;344: 1523-1528.
36. Michelson EL. Clinical perspectives in management of Wolff-Parkinson-White syndrome. Part 2: Diagnostic evaluation and treatment strategies. Mod Concepts Cardiovasc Dis 1989;58:49-54.
37. Jackman WM, Wang X, Friday KJ et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991;324:1605-1611.
38. Aronow WS, Mercando AD, Epstein S. Prevalence of arrhythmias detected by 24-hour ambulatory electrocardiography and value of antiarrhythmic therapy in elderly patients with unexplained syncope. Am J Cardiol 1992;70: 408-410.
39. Morris JJ Jr, Peter RH, McIntosh HD. Electrical conversion of atrial fibrillation: Immediate and long-term results and selection of patients. Ann Intern Med 1966;65:216-231.
40. Feld GK, Chen P-S, Nicod P et al. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990;66:378-383.
41. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992;117:141-150.
42. Maisel WH, Kuntz KM, Reimold SC et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997;127:281-284.
43. Cardiac Arrhythmia Suppression Trial. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;329:406-412.
44. Ellenbogen KA, Stambler BS, Wood MA et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996;28:130-136.
45. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a Class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997;29:385-390.
46. Manning WJ, Silverman DI, Keighley CS et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study. J Am Coll Cardiol 1995;25:1354-1361.
47. Laupacis A, Albers G, Dalen J et al. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579-589S.
48. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: Evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994;23:307-316.
49. Black IW, Fatkin D, Sagar KB et al. Exclusion of atrial thrombus by trans-esophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study. Circulation 1994;89:2509-2513.
50. Grimm RA, Stewart WJ, Black IW et al. Should all patients undergo transesophageal echocardiography before electrical cardioversion of atrial fibrillation? J Am Coll Cardiol 1994;23:533-541.
51. Coplen SE, Antmann EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
52. Aronow WS, Mercando AD, Epstein S, Kronzon I. Effect of quinidine or procainimide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1990;66:423-428.
53. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
54. Reimold SC, Cantillon CO, Friedman PL et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563.
55. Flaker GC, Blackshear JL, McBride R et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532.
56. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
57. Murgatroyd FD, Xie B, Gibson SM et al. The effects of digoxin in patients with paroxysmal atrial fibrillation: Analysis of Holter data from the CRAFT-1 Trial. J Am Coll Cardiol (abstract) 1993;21:203A.
58. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990;63:225-227.
59. Galun E, Flugelman MY, Glickson M, Eliakim M. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991;99:1038-1040.
60. Aronow WS, Ahn C, Mercando AD et al. Effect of propranolol versus no antiarrhythmic drug on sudden death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol 1994;74: 267-270.
61. Olshansky B. Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol 1996;78(suppl 8A):27-34.
62. Brignole M, Menozzi C, Gianfranchi L et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. A randomized, controlled study. Circulation 1998;98:953-960.
63. Planning and Steering Committees for AFFIRM Study. Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM Study design. Am J Cardiol 1997;79:1198-1202.
64. Wellens HJJ, Lau C-P, Luderitz B et al. Atrioverter: An implantable device for the treatment of atrial fibrillation. Circulation 1998;98:1651-1656.
65. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
66. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
67. Aronow WS, Ahn C, Mercando AD et al. Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients. Aging Clin Exp Res 1996;8:32-34.
68. Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation. Am J Cardiol 1998;82:119-121.
69. Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol 1989;63: 366-367.
70. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
71. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
72. Aronow WS, Ahn C, Schoenfeld MR, Gutstein H. Association of extracranial carotid arterial disease and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 1,846 older persons. Am J Cardiol 1999, 83:1403-1404.
73. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
74. Peterson P, Kastrup J, Helweg-Larsen S et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. Arch Intern Med 1990;150: 819-821.
75. Aronow WS, Ahn C, Kronzon I, Gutstein H. Association of mitral annular calcium with new thromboembolic stroke at 44-month follow-up of 2,148 persons, mean age 81 years. Am J Cardiol 1998;81:105-106.
76. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
77. Peterson P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989;1:175-179.
78. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990;322:863-868.
79. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991;84:527-539.
80. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:345-355.
81. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327:1406-1412.
82. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
83. Aronow WS, Ahn C, Kronzon I, Gutstein H. Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc 1999;47:366-368.
84. Gullov AL, Koefoed BG, Petersen P et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-1521.
85. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998;279:1273-1277.
86. Aronow WS. Cardiovascular drug therapy in the elderly. In: WH Frishman, ED Sonnenblick (eds). Cardiovascular Pharmacotherapeutics. New York: McGraw-Hill, Inc, 1997, pp 1267-1281.